0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Anti-Parkinson Drugs Market Research Report 2024
Published Date: January 2024
|
Report Code: QYRE-Auto-16F6021
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Anti Parkinson Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global Anti-Parkinson Drugs Market Research Report 2024

Code: QYRE-Auto-16F6021
Report
January 2024
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Anti-Parkinson Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Anti-Parkinson Drugs Market

Anti-Parkinson Drugs Market

Anti-Parkinson Drugs are drugs used to treat Parkinson's disease.
The global Anti-Parkinson Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-Parkinson Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Parkinson Drugs.

Report Scope

The Anti-Parkinson Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Parkinson Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Parkinson Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Anti-Parkinson Drugs Market Report

Report Metric Details
Report Name Anti-Parkinson Drugs Market
CAGR 5%
Segment by Type
  • Dopaminergic
  • Dopamine Agonists
  • Enzyme Inhibitors
  • Others
Segment by Application
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AbbVie, Mylan Laboratories, Valeant Pharmaceuticals, Novartis, GlaxoSmithKline, Zambon Pharmaceuticals, Pfizer, Inc., Hoffmann-La Roche, Merck & Co., Orion Pharma, UCB, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Anti-Parkinson Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Anti-Parkinson Drugs Market report?

Ans: The main players in the Anti-Parkinson Drugs Market are AbbVie, Mylan Laboratories, Valeant Pharmaceuticals, Novartis, GlaxoSmithKline, Zambon Pharmaceuticals, Pfizer, Inc., Hoffmann-La Roche, Merck & Co., Orion Pharma, UCB, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc.

What are the Application segmentation covered in the Anti-Parkinson Drugs Market report?

Ans: The Applications covered in the Anti-Parkinson Drugs Market report are Hospital Pharmacy, Retail Pharmacy, Online Stores

What are the Type segmentation covered in the Anti-Parkinson Drugs Market report?

Ans: The Types covered in the Anti-Parkinson Drugs Market report are Dopaminergic, Dopamine Agonists, Enzyme Inhibitors, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Dopaminergic
1.2.3 Dopamine Agonists
1.2.4 Enzyme Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Anti-Parkinson Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Stores
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-Parkinson Drugs Market Perspective (2019-2030)
2.2 Anti-Parkinson Drugs Growth Trends by Region
2.2.1 Global Anti-Parkinson Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-Parkinson Drugs Historic Market Size by Region (2019-2024)
2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Region (2025-2030)
2.3 Anti-Parkinson Drugs Market Dynamics
2.3.1 Anti-Parkinson Drugs Industry Trends
2.3.2 Anti-Parkinson Drugs Market Drivers
2.3.3 Anti-Parkinson Drugs Market Challenges
2.3.4 Anti-Parkinson Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-Parkinson Drugs Players by Revenue
3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2019-2024)
3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-Parkinson Drugs Revenue
3.4 Global Anti-Parkinson Drugs Market Concentration Ratio
3.4.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2023
3.5 Anti-Parkinson Drugs Key Players Head office and Area Served
3.6 Key Players Anti-Parkinson Drugs Product Solution and Service
3.7 Date of Enter into Anti-Parkinson Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-Parkinson Drugs Breakdown Data by Type
4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2019-2024)
4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2025-2030)
5 Anti-Parkinson Drugs Breakdown Data by Application
5.1 Global Anti-Parkinson Drugs Historic Market Size by Application (2019-2024)
5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-Parkinson Drugs Market Size (2019-2030)
6.2 North America Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-Parkinson Drugs Market Size by Country (2019-2024)
6.4 North America Anti-Parkinson Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-Parkinson Drugs Market Size (2019-2030)
7.2 Europe Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-Parkinson Drugs Market Size by Country (2019-2024)
7.4 Europe Anti-Parkinson Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-Parkinson Drugs Market Size (2019-2030)
8.2 Asia-Pacific Anti-Parkinson Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-Parkinson Drugs Market Size (2019-2030)
9.2 Latin America Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-Parkinson Drugs Market Size by Country (2019-2024)
9.4 Latin America Anti-Parkinson Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-Parkinson Drugs Market Size (2019-2030)
10.2 Middle East & Africa Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Anti-Parkinson Drugs Introduction
11.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Mylan Laboratories
11.2.1 Mylan Laboratories Company Detail
11.2.2 Mylan Laboratories Business Overview
11.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction
11.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.2.5 Mylan Laboratories Recent Development
11.3 Valeant Pharmaceuticals
11.3.1 Valeant Pharmaceuticals Company Detail
11.3.2 Valeant Pharmaceuticals Business Overview
11.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction
11.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.3.5 Valeant Pharmaceuticals Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Anti-Parkinson Drugs Introduction
11.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Zambon Pharmaceuticals
11.6.1 Zambon Pharmaceuticals Company Detail
11.6.2 Zambon Pharmaceuticals Business Overview
11.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction
11.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.6.5 Zambon Pharmaceuticals Recent Development
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Company Detail
11.7.2 Pfizer, Inc. Business Overview
11.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction
11.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.7.5 Pfizer, Inc. Recent Development
11.8 Hoffmann-La Roche
11.8.1 Hoffmann-La Roche Company Detail
11.8.2 Hoffmann-La Roche Business Overview
11.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction
11.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.8.5 Hoffmann-La Roche Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Detail
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Anti-Parkinson Drugs Introduction
11.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.9.5 Merck & Co. Recent Development
11.10 Orion Pharma
11.10.1 Orion Pharma Company Detail
11.10.2 Orion Pharma Business Overview
11.10.3 Orion Pharma Anti-Parkinson Drugs Introduction
11.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.10.5 Orion Pharma Recent Development
11.11 UCB
11.11.1 UCB Company Detail
11.11.2 UCB Business Overview
11.11.3 UCB Anti-Parkinson Drugs Introduction
11.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.11.5 UCB Recent Development
11.12 Teva Pharmaceutical Industries Ltd.
11.12.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction
11.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.12.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.13 Vertical Pharmaceuticals, LLC
11.13.1 Vertical Pharmaceuticals, LLC Company Detail
11.13.2 Vertical Pharmaceuticals, LLC Business Overview
11.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction
11.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.13.5 Vertical Pharmaceuticals, LLC Recent Development
11.14 ACADIA Pharmaceuticals Inc.
11.14.1 ACADIA Pharmaceuticals Inc. Company Detail
11.14.2 ACADIA Pharmaceuticals Inc. Business Overview
11.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction
11.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.14.5 ACADIA Pharmaceuticals Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Anti-Parkinson Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Dopaminergic
    Table 3. Key Players of Dopamine Agonists
    Table 4. Key Players of Enzyme Inhibitors
    Table 5. Key Players of Others
    Table 6. Global Anti-Parkinson Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Anti-Parkinson Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Anti-Parkinson Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 9. Global Anti-Parkinson Drugs Market Share by Region (2019-2024)
    Table 10. Global Anti-Parkinson Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 11. Global Anti-Parkinson Drugs Market Share by Region (2025-2030)
    Table 12. Anti-Parkinson Drugs Market Trends
    Table 13. Anti-Parkinson Drugs Market Drivers
    Table 14. Anti-Parkinson Drugs Market Challenges
    Table 15. Anti-Parkinson Drugs Market Restraints
    Table 16. Global Anti-Parkinson Drugs Revenue by Players (2019-2024) & (US$ Million)
    Table 17. Global Anti-Parkinson Drugs Market Share by Players (2019-2024)
    Table 18. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2023)
    Table 19. Ranking of Global Top Anti-Parkinson Drugs Companies by Revenue (US$ Million) in 2023
    Table 20. Global 5 Largest Players Market Share by Anti-Parkinson Drugs Revenue (CR5 and HHI) & (2019-2024)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Anti-Parkinson Drugs Product Solution and Service
    Table 23. Date of Enter into Anti-Parkinson Drugs Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Anti-Parkinson Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 26. Global Anti-Parkinson Drugs Revenue Market Share by Type (2019-2024)
    Table 27. Global Anti-Parkinson Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 28. Global Anti-Parkinson Drugs Revenue Market Share by Type (2025-2030)
    Table 29. Global Anti-Parkinson Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 30. Global Anti-Parkinson Drugs Revenue Market Share by Application (2019-2024)
    Table 31. Global Anti-Parkinson Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 32. Global Anti-Parkinson Drugs Revenue Market Share by Application (2025-2030)
    Table 33. North America Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 34. North America Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 35. North America Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 36. Europe Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. Europe Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 38. Europe Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Asia-Pacific Anti-Parkinson Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 40. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 41. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2025-2030) & (US$ Million)
    Table 42. Latin America Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 43. Latin America Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 46. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 47. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 48. AbbVie Company Detail
    Table 49. AbbVie Business Overview
    Table 50. AbbVie Anti-Parkinson Drugs Product
    Table 51. AbbVie Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 52. AbbVie Recent Development
    Table 53. Mylan Laboratories Company Detail
    Table 54. Mylan Laboratories Business Overview
    Table 55. Mylan Laboratories Anti-Parkinson Drugs Product
    Table 56. Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 57. Mylan Laboratories Recent Development
    Table 58. Valeant Pharmaceuticals Company Detail
    Table 59. Valeant Pharmaceuticals Business Overview
    Table 60. Valeant Pharmaceuticals Anti-Parkinson Drugs Product
    Table 61. Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 62. Valeant Pharmaceuticals Recent Development
    Table 63. Novartis Company Detail
    Table 64. Novartis Business Overview
    Table 65. Novartis Anti-Parkinson Drugs Product
    Table 66. Novartis Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 67. Novartis Recent Development
    Table 68. GlaxoSmithKline Company Detail
    Table 69. GlaxoSmithKline Business Overview
    Table 70. GlaxoSmithKline Anti-Parkinson Drugs Product
    Table 71. GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 72. GlaxoSmithKline Recent Development
    Table 73. Zambon Pharmaceuticals Company Detail
    Table 74. Zambon Pharmaceuticals Business Overview
    Table 75. Zambon Pharmaceuticals Anti-Parkinson Drugs Product
    Table 76. Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 77. Zambon Pharmaceuticals Recent Development
    Table 78. Pfizer, Inc. Company Detail
    Table 79. Pfizer, Inc. Business Overview
    Table 80. Pfizer, Inc. Anti-Parkinson Drugs Product
    Table 81. Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 82. Pfizer, Inc. Recent Development
    Table 83. Hoffmann-La Roche Company Detail
    Table 84. Hoffmann-La Roche Business Overview
    Table 85. Hoffmann-La Roche Anti-Parkinson Drugs Product
    Table 86. Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 87. Hoffmann-La Roche Recent Development
    Table 88. Merck & Co. Company Detail
    Table 89. Merck & Co. Business Overview
    Table 90. Merck & Co. Anti-Parkinson Drugs Product
    Table 91. Merck & Co. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 92. Merck & Co. Recent Development
    Table 93. Orion Pharma Company Detail
    Table 94. Orion Pharma Business Overview
    Table 95. Orion Pharma Anti-Parkinson Drugs Product
    Table 96. Orion Pharma Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 97. Orion Pharma Recent Development
    Table 98. UCB Company Detail
    Table 99. UCB Business Overview
    Table 100. UCB Anti-Parkinson Drugs Product
    Table 101. UCB Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 102. UCB Recent Development
    Table 103. Teva Pharmaceutical Industries Ltd. Company Detail
    Table 104. Teva Pharmaceutical Industries Ltd. Business Overview
    Table 105. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Product
    Table 106. Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 107. Teva Pharmaceutical Industries Ltd. Recent Development
    Table 108. Vertical Pharmaceuticals, LLC Company Detail
    Table 109. Vertical Pharmaceuticals, LLC Business Overview
    Table 110. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Product
    Table 111. Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 112. Vertical Pharmaceuticals, LLC Recent Development
    Table 113. ACADIA Pharmaceuticals Inc. Company Detail
    Table 114. ACADIA Pharmaceuticals Inc. Business Overview
    Table 115. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Product
    Table 116. ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
    Table 117. ACADIA Pharmaceuticals Inc. Recent Development
    Table 118. Research Programs/Design for This Report
    Table 119. Key Data Information from Secondary Sources
    Table 120. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Anti-Parkinson Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Anti-Parkinson Drugs Market Share by Type: 2023 VS 2030
    Figure 3. Dopaminergic Features
    Figure 4. Dopamine Agonists Features
    Figure 5. Enzyme Inhibitors Features
    Figure 6. Others Features
    Figure 7. Global Anti-Parkinson Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global Anti-Parkinson Drugs Market Share by Application: 2023 VS 2030
    Figure 9. Hospital Pharmacy Case Studies
    Figure 10. Retail Pharmacy Case Studies
    Figure 11. Online Stores Case Studies
    Figure 12. Anti-Parkinson Drugs Report Years Considered
    Figure 13. Global Anti-Parkinson Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 14. Global Anti-Parkinson Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Anti-Parkinson Drugs Market Share by Region: 2023 VS 2030
    Figure 16. Global Anti-Parkinson Drugs Market Share by Players in 2023
    Figure 17. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2023)
    Figure 18. The Top 10 and 5 Players Market Share by Anti-Parkinson Drugs Revenue in 2023
    Figure 19. North America Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. North America Anti-Parkinson Drugs Market Share by Country (2019-2030)
    Figure 21. United States Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Canada Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Anti-Parkinson Drugs Market Share by Country (2019-2030)
    Figure 25. Germany Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. France Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. U.K. Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Italy Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Russia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Nordic Countries Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Asia-Pacific Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Asia-Pacific Anti-Parkinson Drugs Market Share by Region (2019-2030)
    Figure 33. China Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Japan Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. South Korea Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Southeast Asia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. India Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Australia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Latin America Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Latin America Anti-Parkinson Drugs Market Share by Country (2019-2030)
    Figure 41. Mexico Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Brazil Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Middle East & Africa Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Middle East & Africa Anti-Parkinson Drugs Market Share by Country (2019-2030)
    Figure 45. Turkey Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Saudi Arabia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. AbbVie Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 48. Mylan Laboratories Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 49. Valeant Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 50. Novartis Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 51. GlaxoSmithKline Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 52. Zambon Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 53. Pfizer, Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 54. Hoffmann-La Roche Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 55. Merck & Co. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 56. Orion Pharma Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 57. UCB Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 58. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 59. Vertical Pharmaceuticals, LLC Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 60. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS